HOOKIPA Pharma (NASDAQ:HOOK – Get Free Report) is expected to be issuing its results before the market opens on Friday, February 27th. Analysts expect HOOKIPA Pharma to post earnings of ($0.76) per share and revenue of $3.3750 million for the quarter.
HOOKIPA Pharma Price Performance
NASDAQ HOOK opened at $1.05 on Thursday. HOOKIPA Pharma has a one year low of $0.72 and a one year high of $1.77. The business has a 50 day simple moving average of $0.97 and a 200 day simple moving average of $0.92. The stock has a market capitalization of $12.80 million, a P/E ratio of -0.18 and a beta of 0.92.
About HOOKIPA Pharma
HOOKIPA Pharma Inc is a clinical-stage biotechnology company focused on the development of virus-based immunotherapies and vaccines. The company operates two complementary platform technologies—an engineered Modified Vaccinia Ankara (MVA) vector and an arenavirus vector system—designed to stimulate both humoral and cellular immune responses. By combining these platforms, HOOKIPA aims to address infectious diseases and drive novel immuno-oncology treatments.
In the infectious disease arena, HOOKIPA’s pipeline includes prophylactic vaccine candidates targeting pathogens such as cytomegalovirus (CMV) in transplant settings and other viral threats.
Read More
- Five stocks we like better than HOOKIPA Pharma
- Buffett, Gates and Bezos Quietly Dumping Stocks—Here’s Why
- ALERT: Drop these 5 stocks before the market opens tomorrow!
- Elon Musk: This Could Turn $100 into $100,000
- Read this or regret it forever
- The Next Commodity Crunch (bigger than oil?)
Receive News & Ratings for HOOKIPA Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HOOKIPA Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
